How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment.

Am J Clin Oncol 2011 Dec;34(6):625-7

Department of Experimental Medicine, Sapienza University of Rome, Italy.

Resistance to anthracyclines is responsible for treatment failure in most patients with metastatic breast cancer. According to recent studies, the expression of specific drug transporters (MRPs) on circulating tumor cells is predictive of prognosis in different cancer types. We observed that patients whose circulating tumor cells expressed MRP1 and MRP2, two drug-export pumps responsible for anthracyclines efflux, who received conventional anthracyclines had a significantly shorter time to progression compared with patients sharing same characteristics who received non pegylated liposomal doxorubicin (P < 0.005). These results may highlight a new appealing role of the liposomal doxorubicin formulation, not only because of its reduced cardiac toxicity but especially referring to its theoretical efficacy in anthracycline-resistant breast cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181f94596DOI Listing
December 2011
6 Reads

Publication Analysis

Top Keywords

tumor cells
12
breast cancer
12
circulating tumor
12
liposomal doxorubicin
8
metastatic breast
8
expressed mrp1
4
cells expressed
4
doxorubicin formulation
4
patients circulating
4
role liposomal
4
appealing role
4
mrp2 drug-export
4
observed patients
4
mrp1 mrp2
4
cancer types
4
reduced cardiac
4
pegylated liposomal
4
transporters mrps
4
cells predictive
4
predictive prognosis
4

Similar Publications